Epizyme’s Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models
Epizyme Inc (NASDAQ:EPZM) has reported positive data from mouse studies for potential first-in-class therapy, EPZ-719, that targets the enzyme SETD2. The…
Centene To Pay $143.3M To Settle Ohio, Mississippi Suit Over Double-Billing On Medicaid Drugs
Centene Corporation (NYSE:CNC) has agreed to pay Ohio $88.3 million to settle a lawsuit accusing the company of making off with…
Omeros’ Narsoplimab Associated With Improvement In Organ Function In Stem Cell Transplant Patients
Omeros Corporation (NASDAQ:OMER) has announced the presentation of data on organ function improvement from its pivotal trial of narsoplimab for the…
Terns Shares Drop After Mixed Results From Mid-Stage NASH Trial With FXR Agonist
Terns Pharmaceuticals Inc (NASDAQ:TERN) reported top-line results from the Phase 2a LIFT trial of TERN-101, a liver-distributed farnesoid X receptor (FXR)…
Brooklyn ImmunoTherapeutics Stock Rises After Novellus Therapeutics Buyout Deal
Brooklyn ImmunoTherapeutics LLC (NYSE:BTX) has executed a non-binding letter of intent to acquire Novellus Therapeutics, a company developing engineered mesenchymal stem…
Philips Recalls Ventilators And Sleep Apnea Devices Due To Possible Health Risks
The Dutch medical equipment firm Koninklijke Philips NV (OTC: RYLPF) has recalled several of its sleep apnea and respiratory care devices due to potential health risks.
Cocrystal Pharma’s Preclinical Protease Inhibitor Effective Against Original, Two Variant COVID-19 Strains
Cocrystal Pharma Inc (NASDAQ:COCP) has announced laboratory-based results for its lead preclinical SARS-CoV-2 3CL protease inhibitor, CDI-45205. A third-party laboratory contracted…
Lipocine To Start Testing Neuro-Steroid Candidate In Postpartum Depression Patients
The FDA has signed off Lipocine Inc’s (NASDAQ:LPCN) Investigational New Drug Application (IND) to initiate a Phase 2 study to evaluate…
G1 Therapeutics Starts Mid-Stage Bladder Cancer Trial With Cosela
G1 Therapeutics Inc (NASDAQ:GTHX) has initiated the PRESERVE 3 Phase 2 study evaluating Cosela (trilaciclib) in patients with untreated, locally advanced,…
EyeGate Pharma Stock Jumps On Initiation Of Proof Of Concept Trial With DHODH Inhibitor In Ophthalmology Indications
EyeGate Pharmaceuticals Inc (NASDAQ:EYEG) has dosed the patient in Phase 2 proof-of-concept study evaluating its lead product candidate, PP-001, in patients…